Aleniglipron achieves up to 16% weight loss in Phase 2 ACCESS II trial; Phase III planned for Q3 2026

Structure Therapeutics/Aleniglipron

Structure reported 44-week topline data from Phase 2 ACCESS II showing that aleniglipron achieved weight loss of up to 16% at the highest dose, competitive with injectable GLP-1 drugs. The company announced plans to initiate Phase III registration trials in Q3 2026.

• Phase 2 ACCESS II trial showed 44-week weight loss up to 16%.
• Efficacy was dose-dependent and competitive with injectable GLP-1s.
• No off-target safety signals observed; fewer than 5% discontinued due to adverse events.
• Phase III program planned for Q3 2026 with ~4,700 patients.